Drug Prices
The latest report from a group financed and backed by the pharmaceutical industry 鈥渃ontinues to misrepresent鈥 the 340B Drug Pricing Program and its 鈥渟uccessful 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and鈥
The latest report from AIR340B, a group financed and backed by the pharmaceutical industry, continues to misrepresent a program with a successful 25-year history of helping hospitals stretch scarce financial resources to expand and improve access to lifesaving prescription drugs and comprehensive鈥
Fifty-seven senators Friday urged the Centers for Medicare & Medicaid Services (CMS) to 鈥渃arefully consider stakeholder feedback鈥 before the agency finalizes its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program. 鈥淭he long-term success of the鈥
Once again, the Senate attempted to pass a proposal to repeal and replace significant parts of the Affordable Care Act. Once again, it met defeat 鈥 and we are grateful.But this fight is not over. America鈥檚 hospitals and health systems must stay vigilant and continue to make the case to protect鈥
The panel that advises the Centers for Medicare & Medicaid Services on hospital outpatient payments sent a clear signal to the agency this week: Don鈥檛 shortchange patients鈥 access to vital pharmaceuticals by cutting the 340B Drug Pricing Program. CMS鈥檚 Advisory Panel on Hospital Outpatient鈥
The House Energy & Commerce Subcommittee on Oversight and Investigations today held a hearing to review the Health Resources and Services Administration鈥檚 oversight of the 340B Drug Pricing Program and how the program impacts patients, providers, manufacturers and other stakeholders.
Today, CMS issued several poorly designed policies that will do real damage to patients access to care.